KEYNOTE-119: Phase 3 study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple-negative breast cancer (mTNBC).

What’s needed next to meet the challenges in ER+ve breast cancer care?

Strategies to consider to improve the slow progress in ER+ve BC and the risk of relapse

Trans-aTTom: To offer more?

Neoadjuvant vs adjuvant approaches in early TNBC